Seeing Is Believing
Currently out of the existing stock ratings of Pete Stavropoulos, 40 are a BUY (97.56%), 1 are a HOLD (2.44%).
Analyst Pete Stavropoulos, currently employed at CANTOR FITZGERALD, carries an average stock price target met ratio of 31.11% that have a potential upside of 69.16% achieved within 159 days.
Pete Stavropoulos’s has documented 69 price targets and ratings displayed on 10 stocks. The coverage is on the Healthcare sector.
Most recent stock forecast was given on VERA, Vera Therapeutics at 07-May-2025.
Analyst best performing recommendations are on ORTX (ORCHARD THERAPEUTICS PLC).
The best stock recommendation documented was for ORTX (ORCHARD THERAPEUTICS PLC) at 6/27/2023. The price target of $15 was fulfilled within 100 days with a profit of $9.77 (186.81%) receiving and performance score of 18.68.
Average potential price target upside
Analyst name
Rating
Current price target
Potential Upside
Previous price target
Date
Price targets met ratio
Average potential upside
Average Days to Hit Target
Performance score
Buy
5 months 5 days ago
(13-May-2025)
0/11 (0%)
$9.88 (161.44%)
Buy
5 months 5 days ago
(13-May-2025)
0/3 (0%)
$23.88 (390.20%)
Buy
11 months 3 days ago
(15-Nov-2024)
0/5 (0%)
$10.05 (340.68%)
Buy
$14
$10.85 (344.44%)
$10
1 years 4 months 13 days ago
(05-Jun-2024)
0/4 (0%)
$7.21 (106.19%)
Buy
$12
$8.85 (280.95%)
$10
1 years 4 months 14 days ago
(04-Jun-2024)
4/6 (66.67%)
$6.01 (100.33%)
106
Which stock is Pete Stavropoulos is most bullish on?
What Year was the first public recommendation made by Pete Stavropoulos?